Biotech is undoubtedly one of the most volatile businesses on the planet. John Maraganore of Alnylam knows that well. The CEO of Alnylam Pharmaceuticals has been there for the whole classic biotech roller coaster ride. Back in the early 2000s, scientists were electrified by the possibilities to treat the untreatable with RNA interference drug technology. Then, pharma companies ran for... Read More
Questions and comments have been pouring in here at Timmerman Report headquarters ever since the site debuted on Feb. 2. The early days have been nothing short of spectacular in my view. I’ll have more to say about that shortly. But for now, there are some of answers to the questions that keep popping up: Q: What do you cover?
The guy who helped popularize the gene chip is at it again. Stephen Fodor, whose work on DNA microarrays in the 1990s enabled the large-scale analysis of gene expression–the extent to which genes are turned on or off in a sample—is imaging new ways to take samples and extract more information out of them. Last month, Fodor, 61, stepped down... Read More
The Timmerman Report Gives You Consistent In-Depth Reporting on Biotechnology. Get Your Edge.